Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 2/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14548867 | 1.00 | CA1 (0.38) | CA1CA12CA7CA14CA2 | |
| SCHEMBL22022206 | 1.00 | CA1 (0.38) | CA1CA12CA7CA14CA2 | |
| SCHEMBL5075567 | 1.00 | CA1 (0.38) | CA1CA12CA7CA14CA2 | |
| SCHEMBL159029 | 1.00 | CA1 (0.38) | CA1CA12CA7CA14CA2 | |
| SCHEMBL14641415 | 1.00 | CA1 (0.38) | CA1CA12CA7CA14CA2 | |
| SCHEMBL14463171 | 1.00 | CA1 (0.38) | CA1CA12CA7CA14CA2 | |
| SCHEMBL15856951 | 1.00 | CA1 (0.38) | CA1CA12CA7CA14CA2 | |
| SCHEMBL18811684 | 1.00 | CA1 (0.38) | CA1CA12CA7CA14CA2 | |
| Hydrogen Sulfide SCHEMBL27532786 | 0.97 | CA1 (0.36) | CA1CA12CA7CA14CA2 | |
| SCHEMBL68569 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022109001-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-05-27 | — | — | WO | disclosed |
| US-11129790-B2 | Chemo-enzymatic site-specific modification of peptides and proteins to form cleavable conjugates | NORTHEASTERN UNIVERSITY (US) | 2021-09-28 | — | — | US | disclosed |
| CN-108863919-B | Sulfonamide compound for treating gout or hyperuricemia and preparation method thereof | 海创药业股份有限公司 | 2021-04-02 | — | — | CN | disclosed |
| US-20200133121-A1 | ONIUM SALT, NEGATIVE RESIST COMPOSITION, AND RESIST PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-3644122-A1 | ONIUM SALT, NEGATIVE RESIST COMPOSITION, AND RESIST PATTERN FORMING PROCESS | Shin-Etsu Chemical Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| CN-106973990-B | fumigation method for preventing and controlling entomophthora in grains | 中国科学院上海有机化学研究所 | 2019-12-10 | — | — | CN | disclosed |
| WO-2019113476-A2 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-06-13 | — | — | WO | disclosed |
| CN-108863919-A | For treating the sulfamide compound and preparation method thereof of gout or hyperuricemia | 成都海创药业有限公司 | 2018-11-23 | — | — | CN | disclosed |
| US-20180334436-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | VIIV HEALTHCARE UK LIMITED (GB) | 2018-11-22 | — | — | US | disclosed |
| EP-3383866-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | ViiV Healthcare UK Limited (GB) | 2018-10-10 | — | — | EP | disclosed |
| EP-0788796-A1 | URICOSURIC AGENT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-13 | — | — | EP | disclosed |
| US-4629811-A | 3-sulfonylamino-4-aminobenzophenone derivatives | ELI LILLY AND COMPANY (US) | 1986-12-16 | — | — | US | disclosed |
| US-4483986-A | 4-Nitrobenzophenone compounds | ELI LILLY AND COMPANY (US) | 1984-11-20 | — | — | US | disclosed |
| EP-0093590-A1 | Process for the preparation of sulfonylamino benzophenones | ELI LILLY AND COMPANY (US) | 1983-11-09 | — | — | EP | disclosed |
| US-4401817-A | ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1983-08-30 | — | — | US | disclosed |
| US-4338329-A | COMBATTING RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| US-4289782-A | PARTICULARLY FOR INHIBITING GROWTH OF RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| US-4230868-A | α-Alkyl-α-hydroxybenzyl-substituted 1-sulfonylbenzimidazoles | ELI LILLY AND COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
| US-4174454-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1979-11-13 | — | — | US | disclosed |
| US-4118742-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200133121-A1 | ONIUM SALT, NEGATIVE RESIST COMPOSITION, AND RESIST PATTERN FORMING PROCESS | SLC6A5, SLC11A2, LARP7 | CA1 2060/4885CA12 1917/4885CA7 225/4885 |
| US-11129790-B2 | Chemo-enzymatic site-specific modification of peptides and proteins to form cleavable conjugates | GLUL, QPCT, DNPEP | CA1 167/4885CA12 331/4885CA7 560/4885 |
| US-20180334436-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | MAVS, EIF2AK2, SARS1 | CA1 3074/4885CA12 3567/4885CA7 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.